Literature DB >> 9740112

Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease.

V Haroutunian1, D P Perl, D P Purohit, D Marin, K Khan, M Lantz, K L Davis, R C Mohs.   

Abstract

BACKGROUND: Identification of the neuropathological lesions that are most closely associated with the earliest symptoms of Alzheimer disease (AD) is crucial to the understanding of the disease process and the development of treatment strategies to affect its progress. Do the classical neuropathological lesions of AD precede, follow, or occur in synchrony with the earliest signs of cognitive deterioration? DESIGN AND OUTCOME MEASURES: We examined the extent of neuritic plaque (NP) formation in 5 neocortical regions and the hippocampus, entorhinal cortex, and amygdala in 66 elderly subjects with no dementia, questionable dementia, or mild dementia as assessed using the Clinical Dementia Rating Scale (CDR). SETTING AND PATIENTS: Postmortem study of nursing home residents.
RESULTS: Even questionable dementia (CDR, 0.5) was associated with a significant (P = .04) increase in neocortical NP density. The density of NPs increased further with increasing dementia severity in all brain regions examined. However, subjects with questionable dementia or definite but mild dementia did not differ significantly from each other. Density of NPs was nearly maximal in subjects with moderate dementia (CDR = 2.0), suggesting that other neuropathological changes may be responsible for cognitive deficits beyond this level. Dementia severity correlated significantly with the density of NPs in all brain regions examined (r range, 0.47-0.56; P < .001), even when subjects with a CDR of 0 were excluded.
CONCLUSIONS: These findings are consistent with the hypothesis that NPs are among the earliest neuropathological lesions in AD. Even very mild or questionable dementia is associated with increased density of neocortical NPs that do not distinguish between clinically questionable vs definite dementia.

Entities:  

Mesh:

Year:  1998        PMID: 9740112     DOI: 10.1001/archneur.55.9.1185

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  95 in total

1.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

2.  Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease.

Authors:  Liana G Apostolova; Kristy S Hwang; Luis D Medina; Amity E Green; Meredith N Braskie; Rebecca A Dutton; Jeffrey Lai; Daniel H Geschwind; Jeffrey L Cummings; Paul M Thompson; John M Ringman
Journal:  Dement Geriatr Cogn Disord       Date:  2011-09-23       Impact factor: 2.959

3.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk
Journal:  Acta Neuropathol       Date:  2012-01-24       Impact factor: 17.088

4.  Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.

Authors:  Michal Schnaider Beeri; Jeremy M Silverman; Kenneth L Davis; Deborah Marin; Hillel Z Grossman; James Schmeidler; Dushyant P Purohit; Daniel P Perl; Michael Davidson; Richard C Mohs; Vahram Haroutunian
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-04       Impact factor: 6.053

5.  Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition.

Authors:  Kathryn P Riley; Gregory A Jicha; Daron Davis; Erin L Abner; Gregory E Cooper; Nancy Stiles; Charles D Smith; Richard J Kryscio; Peter T Nelson; Linda J Van Eldik; Frederick A Schmitt
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.

Authors:  Panos Roussos; Pavel Katsel; Peter Fam; Weilun Tan; Dushyant P Purohit; Vahram Haroutunian
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

7.  Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal.

Authors:  Liana G Apostolova; Lisa Mosconi; Paul M Thompson; Amity E Green; Kristy S Hwang; Anthony Ramirez; Rachel Mistur; Wai H Tsui; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2008-09-24       Impact factor: 4.673

8.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  Decreased level of olfactory receptors in blood cells following traumatic brain injury and potential association with tauopathy.

Authors:  Wei Zhao; Lap Ho; Merina Varghese; Shrishailam Yemul; Kristen Dams-O'Connor; Wayne Gordon; Lindsay Knable; Daniel Freire; Vahram Haroutunian; Giulio Maria Pasinetti
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.